Contents 3 min read

Claim and source comparison

The Pizzi 1993, Nakamura 2001, Elston 2014 and Tian 2008 abstracts were compared with the FDA’s dated letter. This limited source reading is not a comprehensive clinical or independent medical review.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Cell / laboratory study

Pizzi et al. (1993) reported potentiation of mGluR responses by aniracetam in rat cell cultures. This does not support an mGluR1/5 antagonism claim; it is not a human anxiety or neurodegeneration treatment result.

Protection and receptor responses in rat cell cultures do not establish effects in the human brain, clinical neurodegeneration treatment or mGluR1/5 antagonism.

Source 4 · Abstract read

Animal study

Nakamura and Kurasawa (2001) tested aniracetam in three mouse anxiety models. Findings suggest cholinergic, dopaminergic and serotonergic involvement; they do not establish human anxiety treatment or greater safety than benzodiazepines.

Behavior and antagonist experiments in mouse models do not demonstrate treatment of human anxiety disorders, increased creativity or superior safety to benzodiazepines.

Source 5 · Abstract read

Animal study

Elston et al. (2014) found no significant group differences in learning, anxiety or other assessed behaviors with oral aniracetam at 50 mg/kg in healthy C57BL/6J mice.

A null mouse experiment does not establish absence of effects in humans; positive animal models likewise cannot establish cognitive enhancement in healthy humans. The 50 mg/kg amount is not a human dose.

Source 7 · Abstract read

Human pharmacokinetic study

Tian et al. (2008) found a parent-aniracetam plasma half-life of about 0.5 hours in 20 healthy men taking 400 mg while fasting. Metabolite duration and perceived effects are separate concepts; this does not establish a need for 2–3 daily doses.

Approximately 0.5 hours describes plasma elimination of parent aniracetam. This bioequivalence experiment between two formulations does not establish clinical efficacy, metabolite duration, personal timing or a need for a fatty meal.

Source 6 · Abstract read

Regulatory scientific assessment

The FDA’s 2019 Peak Nootropics warning letter addresses marketed treatment claims for aniracetam, oxiracetam and pramiracetam products; it does not recognize those products as approved safe and effective treatments.

This is a dated US regulatory record about the named seller and claims; it is not a current global approval map or a clinical experiment measuring a particular adverse-event rate. Online sale does not establish safety or approval.

Source 8 · Official summary read

Our evidence and source methodology

aniracetam: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Aniracetam?

Aniracetam is a fat-soluble racetam. Memory and anxiety mechanisms have mostly been studied preclinically; efficacy and a safe regimen in healthy people have not been established.

Mechanism of Effect

Pizzi et al. (1993) reported potentiation of mGluR responses by aniracetam in rat cell cultures. This does not support an mGluR1/5 antagonism claim; it is not a human anxiety or neurodegeneration treatment result.

Protection and receptor responses in rat cell cultures do not establish effects in the human brain, clinical neurodegeneration treatment or mGluR1/5 antagonism.

Nakamura and Kurasawa (2001) tested aniracetam in three mouse anxiety models. Findings suggest cholinergic, dopaminergic and serotonergic involvement; they do not establish human anxiety treatment or greater safety than benzodiazepines.

Behavior and antagonist experiments in mouse models do not demonstrate treatment of human anxiety disorders, increased creativity or superior safety to benzodiazepines.

Clinical Evidence

Elston et al. (2014) found no significant group differences in learning, anxiety or other assessed behaviors with oral aniracetam at 50 mg/kg in healthy C57BL/6J mice.

A null mouse experiment does not establish absence of effects in humans; positive animal models likewise cannot establish cognitive enhancement in healthy humans. The 50 mg/kg amount is not a human dose.

Tian et al. (2008) found a parent-aniracetam plasma half-life of about 0.5 hours in 20 healthy men taking 400 mg while fasting. Metabolite duration and perceived effects are separate concepts; this does not establish a need for 2–3 daily doses.

Approximately 0.5 hours describes plasma elimination of parent aniracetam. This bioequivalence experiment between two formulations does not establish clinical efficacy, metabolite duration, personal timing or a need for a fatty meal.

Dose information and research limits

There is no validated cognitive or anxiety dose of aniracetam for healthy people. Absorption while fasting was measured in human pharmacokinetic research; it does not establish that a fatty meal is mandatory or that adding choline prevents headaches.

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Safety and Side Effects

The accessed pharmacokinetic and limited clinical data do not establish long-term safe use or the safety of drug combinations. Added choline has not been shown to prevent adverse effects; absence of an interaction record is not evidence of safety.

The FDA’s 2019 Peak Nootropics warning letter addresses marketed treatment claims for aniracetam, oxiracetam and pramiracetam products; it does not recognize those products as approved safe and effective treatments.

This is a dated US regulatory record about the named seller and claims; it is not a current global approval map or a clinical experiment measuring a particular adverse-event rate. Online sale does not establish safety or approval.

Sources

  1. Nakamura K, Tanaka Y. (2001). Antidepressant-like effects of aniracetam in aged rats and its mode of action. Psychopharmacology, 158(2), 205–212. PubMed · PMID 11702095
  2. Ito I, et al. (1990). Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. Journal of Physiology, 424, 533–543. PubMed · PMID 1975272
  3. Cumin R, et al. (1982). Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology, 78(2), 104–111. PubMed · PMID 6817363
  4. Pizzi M, et al. (1993). Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells. Journal of Neurochemistry, 61(2), 683–9. https://doi.org/10.1111/j.1471-4159.1993.tb02173.x PubMed · PMID 8101561
  5. Nakamura K, et al. (2001). Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. European Journal of Pharmacology, 420(1), 33–43. https://doi.org/10.1016/s0014-2999(01)01005-6 PubMed · PMID 11412837
  6. Tian Y, et al. (2008). Pharmacokinetics and bioequivalence study of aniracetam after single-dose administration in healthy Chinese male volunteers. Arzneimittelforschung, 58(10), 497–500. https://doi.org/10.1055/s-0031-1296547 PubMed · PMID 19025058
  7. Elston TW, et al. (2014). Aniracetam does not alter cognitive and affective behavior in adult C57BL/6J mice. PLoS One, 9(8), e104443. https://doi.org/10.1371/journal.pone.0104443 PubMed · PMID 25099639
  8. US Food and Drug Administration. (2019). Warning Letter: Peak Nootropics LLC aka Advanced Nootropics. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-nootropics-llc-aka-advanced-nootropics-557887-02052019 US Food and Drug Administration

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions